TCEAL7抗体TCEAL7一抗抗体Transcriptio
n elongation factor S-II protein-like 7 antibody抗体TCEAL7 Antibody抗体- ￥3900
- CUSABIO
- CN
- CSB-PA023278GA01HU
- 2025年07月12日
- ELISA,WB,IHC
- Rabbit
- Human,Mouse,Rat
企业认证
相关产品推荐更多 >
AKT2抗体AKT2兔多抗抗体/抗体AKT2 (Ab-474) Antibody抗体
￥2024
EFHB抗体EFHB兔多抗抗体EF-hand domain-containing family member B antibody抗体EFHB Antibody抗体
￥440
B4GALT6抗体B4GALT6兔多抗抗体UDP-galactose:beta-N-acetylglucosamine beta-1,4-galactosyltransferase 6 antibody抗体B4GALT6 Antibody, Biotin conjugated抗体
￥880
TRUB1抗体TRUB1兔多抗抗体TRUB1_HUMAN antibody抗体TRUB1 Antibody, Biotin conjugated抗体
￥880SOX11抗体SOX11兔多抗抗体Transcription factor SOX-11 antibody抗体SOX11 Antibody, Biotin conjugated抗体
￥880
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Human TCEAL7
- 亚型：
IgG
- 形态：
Liquid
- 保存条件：
Upon receipt, store at -20℃ or -80℃. Avoid repeated freeze.
- 克隆性：
/
- 标记物：
/
- 适应物种：
Human,Mouse,Rat
- 保质期：
6个月
- 抗原来源：
Homo sapiens (Human)
- 目录编号：
Q9BRU2
- 级别：
优
- 库存：
200
- 供应商：
武汉华美生物工程有限公司
- 宿主：
Rabbit
- 应用范围：
ELISA,WB,IHC
- 浓度：
>95%,Antigen Affinity Purified
- 靶点：
TCEAL7
- 抗体英文名：
TCEAL7 Antibody
- 抗体名：
TCEAL7 antibody;Transcription elongation factor A protein-like 7 antibody;TCEA-like protein 7 antibody;Transcription elongation factor S-II protein-like 7 antibody
- 规格：
100μl
保存缓冲液
PBS with 0.1% Sodium Azide, 50% Glycerol, pH 7.3. -20℃, Avoid freeze / thaw cycles.功能
/风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Mapping Protein Distributions on Polytene Chromosomes by Immunostaining
secondary antibody. For double-labeling experiments, use fluorescence-conjugated secondary antibodies raised to the corresponding type of primary antibody. The dilution factor for each antibody needs to be determined experimentally. Blocking
cells. The catalytic domain of diphtheria toxin catalyzes the NAD+ -dependent ADP-ribosylation of the diphthamide residue in elongation factor 2, resulting in inhibition of protein synthesis (20 ,21 ). As the delivery of a single molecule
【翻译】Development trends for monoclonal antibody cancer therapeutics
has more than tripled since the 1980s, from 4.3 per year in the 1980s to 8.3 per year in the 1990s and 13.3 per year for 2000–2005. One reason for the increased investment in mAbs was the evolution of the discovery technology. The initial method for producing mAbs
技术资料暂无技术资料 索取技术资料
